Broiler Breeder Performance in The Final Phase of Grower

One of the comestibles that have high nutritional value and are easy to obtain is chicken. The higher demand for chicken must be accompanied by an increase in production. It is important for the breeder of broiler chicken to choose high quality Day Old Chick (DOC) from the broiler breeder which also has high quality and productivity. The type of broiler breeder that is grown in PT. Karya Indah Pertiwi is Ross 308. Observations were made when the chickens were 18th to 21st weeks old in 6 henneries totaling about 10,000 chickens. The performance of broiler breeder observed were feed consumption, bodyweight gain, feed conversion ratio, and uniformity. Feed consumption of broiler breeder at 18th to 21st week was 659.4 g/chicken, 700,583 g/chicken, 742,116 g/chicken, 767.2 g/chicken. Bodyweight gain at 18th to 21st week was 143.51 g/chicken, 193.3 g/chicken, 63.43 g/chicken, 167.96 g/chicken. Feed conversion ratio at 18th to 21st week was 4.5, 3.6, 11.6, 4.5. The uniformity at 18th to 21st week was 77%, 81%, 81%, 81%. In conclusion, the value of feed consumption for broiler breeder at PT. Karya Indah Pertiwi was increasing every week. Bodyweight gain at 20th week was lower than 18th, 19th, and 21st week. The value of feed conversion ratio at 20th week was higher than at 18th, 19th, and 21st week. Chicken uniformity value at 18th week was not good it was at 77%, while at the 19th, 20th, and 21st week it was quite good at 81%.

Effects of Dietary Glucose Oxidase Supplementation on the Performance, Apparent Ileal Amino Acids Digestibility, and Ileal Microbiota of Broiler Chickens

This study aimed to investigate the effects of glucose oxidase (GOD) supplementation on growth performance, apparent ileal digestibility (AID) of nutrients, intestinal morphology, and short-chain fatty acids (SCFAs) and microbiota in the ileum of broilers. Six hundred 1-day-old male broilers were randomly allotted to four groups of 10 replicates each with 15 birds per replicate cage. The four treatments included the basal diet without antibiotics (Control) and the basal diet supplemented with 250, 500, or 1000 U GOD/kg diet (E250, E500 or E1000). The samples of different intestinal segments, ileal mucosa, and ileal digesta were collected on d 42. Dietary GOD supplementation did not affect daily bodyweight gain (DBWG) and the ratio of feed consumption and bodyweight gain (FCR) during d 1-21 (p > 0.05); however, the E250 treatment increased DBWG (p = 0.03) during d 22–42 as compared to control. Dietary GOD supplementation increased the AIDs of arginine, isoleucine, lysine, methionine, threonine, cysteine, serine, and tyrosine (p < 0.05), while no significant difference was observed among the GOD added groups. The E250 treatment increased the villus height of the jejunum and ileum. The concentrations of secreted immunoglobulin A (sIgA) in ileal mucosa and the contents of acetic acid and butyric acid in ileal digesta were higher in the E250 group than in the control (p < 0.05), whereas no significant differences among E500, E1000, and control groups. The E250 treatment increased the richness of ileal microbiota, but E500 and E100 treatment did not significantly affect it. Dietary E250 treatment increased the relative abundance of Firmicutes phylum and Lactobacillus genus, while it decreased the relative abundance of genus Escherichina-Shigella (p < 0.05). Phylum Fusobacteria only colonized in the ileal digesta of E500 treated broilers and E500 and E1000 did not affect the relative abundance of Firmicutes phylum and Lactobacillus and Escherichina-Shigella genera as compared to control. These results suggested that dietary supplementation of 250 U GOD/kg diet improves the growth performance of broilers during d 22–42, which might be associated with the alteration of the intestinal morphology, SCFAs composition, and ileal microbiota composition.

Use of Lactobacillus farciminis to improve antioxidant status of Tuj lambs

The aim of this study was to investigate the effects of Lactobacillus farciminis on growth traits and antioxidant status in preweaning and postweaning Tuj lambs. Twenty lambs were divided into four groups, regardless of gender, with a mean live weight of 7.81 ± 0.50 kg. At the start of the experiment, the average age of the lambs was seven days. During the six-week preweaning period, control (C) lambs were fed with colostrum only, and Lactobacillus farciminis was given orally to the treated lambs at 1 g/day/lamb (L1), 2 g/day/lamb (L2) or 4 g/day/lamb (L3). The experiment continued for a total of 22 weeks. During the first six weeks, bodyweight (BW) increased significantly in L1 at the sixth week. Also during this period, bodyweight gain (BWG) in L2 at 2 - 3 weeks and in L3 at 5 - 6 weeks differed from C. In the subsequent period, BW and BWG were not affected by probiotic supplementation. The effects of probiotic supplementation on malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) were significant throughout the experiment, with the effect on glutathione (GSH) also being important in the first six weeks. Thus, Lactobacillus farciminis provided orally to Tuj breed lambs could be used to improve their antioxidant status without compromising growth.

Effects of gender and dietary date palm extract on performance, carcass traits, and antioxidant status of Japanese quail

This research examined effects of gender and dietary inclusion of date palm extract (DPE) on growth, carcass characteristics, oxidative status and serum characteristics of Japanese quail. One thousand chicks were allocated to five replicates of treatment and gender groups composed of 20 chicks. The treatments were a basal diet and four groups augmented with 0.25%, 0.50%, 0.75%, and 1.00% DPE. The interaction of gender and treatment was significant for bodyweight (BW) at 42 days, average daily bodyweight gain (BWG), feed intake (FI), weights of most carcass components, and the serum profile. Females had better performance to 42 days than males (P <0.05). In addition, females had higher hot and cold carcass weights, breast percentage, liver percentage, intestine percentage, total protein, albumin, triglyceride (TRIG), total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress indexes (OSIs) (P <0.001). Males had higher percentages of hot carcass, cold carcass and heart, and their levels of cholesterol (CHOL), high-density lipoprotein (HDL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) values were greater than females (P <0.001). Birds fed 0.50% DPE grew faster, were more efficient, and had heavier live and carcass weights at 42 days than those fed the basal diet. However, treatment effects and their interaction with gender on growth, feed intake and the serum profile were unremarkable compared to the gender main effect. Dietary augmentation with 0.50% DPE might enhance the performance of quail between 14 and 42 days old.

Antidyslipidemic Potential of Water-Soluble Polysaccharides of Ganoderma applanatum in MACAPOS-2-Induced Obese Rats

Increased consumption of high-calorie foods leads to obesity usually associated with metabolic disorders including diabetes, hyperglycemia, and dyslipidemia. Ganoderma applanatum is a nonedible mushroom traditionally used in West Cameroon for the treatment of many diseases including hypertension, diabetes, and hepatitis. This study was designed to investigate the antidyslipidemic potential of water-soluble polysaccharides of G. applanatum in MACAPOS-2- (maize, cassava, palm oil, and sugar) induced obese rats. For this purpose, obesity was induced on 6–8-week-old male Wistar rats with a local high-fat diet for four months. G. applanatum polysaccharides (GAPs) obtained by hot water extraction were orally administered to obese rats for two months at different dose levels (50, 100, and 150 mg/kg bodyweight), and its potential was investigated on food consumption, bodyweight gain, serum, and tissue lipids parameters. GAP extract increased the bodyweight gain by raising the food intake of obese rats. Furthermore, the administration of GAP extract at different dose levels significantly decreased the total cholesterol, triglyceride, low-density lipoprotein cholesterol levels, and the atherogenic index from 50 to 150 mg/kg bodyweight. Conversely, GAP extract improved the high-density lipoprotein cholesterol level in obese rats compared with untreated rats after two months’ study period. These results indicated that GAP extract may be considered as a novel bioactive compound against dyslipidemia and its associated complications.

Efficacy of a live attenuated highly pathogenic PRRSV vaccine against a NADC30-like strain challenge: implications for ADE of PRRSV

Background Porcine reproductive and respiratory syndrome virus (PRRSV) infection can cause severe reproductive failure in sows and respiratory distress in pigs of all ages, leading to major economic losses. To date, there are still no effective strategies to prevent and control PRRSV. Antibody-dependent enhancement (ADE), a phenomenon in which preexisting non-neutralizing antibodies or sub-neutralizing antibodies facilitate virus entry and replication, may be a significant obstacle in the development of effective vaccines for many viruses, including PRRSV. However, the contribution of ADE to PRRSV infection remains controversial, especially in vivo. Whether attenuated PRRSV vaccines prevent or worsen subsequent disease in pigs infected by novel PRRSV strains requires more research. In the present study, in vivo experiments were conducted to evaluate ADE under different immune statuses, which were produced by waiting different lengths of time after vaccination with a commercially available attenuated highly pathogenic PRRSV (HP-PRRSV) vaccine (JXA1-R) before challenging the pigs with a novel heterologous NADC30-like strain. Results Piglets that were vaccinated before being challenged with PRRSV exhibited lower mortality rates, lower body temperatures, higher bodyweight gain, and lower viremia. These results demonstrate that vaccination with JXA1-R alleviated the clinical signs of PRRSV infection in all vaccinated groups. Conclusions The obtained data indicate that the attenuated vaccine test here provided partial protection against the NADC30-like strain HNhx. No signs of enhanced PRRSV infection were observed under the applied experimental conditions. Our results provide some insight into the molecular mechanisms underlying vaccine-induced protection or enhancement in PRRSV.

Combinations of Urochloa hybrid Mulato II and natural pasture hays as a basal diet for growing Farta lambs in Ethiopia

The study was conducted to evaluate the feed intake, digestibility, bodyweight change and carcass characteristics of Farta lambs fed Brachiaria (now: Urochloa) hybrid Mulato II and natural pasture hays in various proportions as a basal diet supplemented with a local concentrate mixture (CM). Twenty-five yearling male Farta lambs with a mean initial body weight of 19.6±0.29 kg (mean±s.e.) were used in feeding (90 days) and digestibility (7 days) trials. The lambs were randomly allocated to the following 5 dietary treatments on the basis of stratified body weight: 100% natural pasture hay (NPH) (T1); 75% NPH+25% Urochloa hybrid Mulato II hay (MH) (T2); 50% NPH+50% MH (T3); 25% NPH+75% MH (T4); and 100% MH (T5). A local concentrate mixture [300 g dry matter (DM)/hd/d] was fed to all animals. Crude protein (CP) concentration of the basal diet increased as proportion of MH in the ration increased (P<0.05). Intake of DM and nutrients, and nutrient digestibility coefficients increased significantly (P<0.05) as proportion of MH in the roughage component of the ration increased. Final body weight, average daily bodyweight gain, feed conversion efficiency and most carcass parameters measured were significantly (P<0.05) higher as proportion of MH increased from 0 to 100% in the basal diet. Based on the biological performance of the experimental lambs, performance of sheep in the region could be enhanced significantly by incorporating MH with native pasture hay and concentrate supplement in feeding rations. Economic assessments would reveal the optimal combinations of native pasture and MH for feeding to achieve particular outcomes. Other improved grass and legume species may fill the same role and should be investigated in differing environments.

Using different levels of energy and protein and their effects on bodyweight and blood chemistry of ostriches

To determine the effect of different dietary energy and protein levels on bodyweight and blood chemistry, 36 ostriches at 2 to 9 weeks of age for feeding conditions and 18 for blood chemistry parameters was used. The birds were divided into six treatment groups. Energy and protein levels of diet were 2400 and 2600 kcal/kg and 20%, 22%, and 24%, respectively. The feed intake and bodyweight gain were determined a weekly. Blood chemical parameters including glucose, HDL, LDL, total cholesterol, triglycerides, total protein, albumin, globulin, aspartate amino-transferase and alanine amino-transferase activity were determined. The highest weight gain during the whole experiment was observed in ostriches offered 2400 kcal · kg−1 dietary energy and 20% protein. The lowest level of total cholesterol and protein was observed in treatment V (2600 kcal · kg−1 dietary energy and 22% protein). The lowest level of glucose and triglycerides was noted after treatment I. The highest albumin and globulin concentrations were in treatment III (2400 kcal · kg−1 dietary energy and 24% protein) and treatment II (2400 kcal · kg−1 dietary energy and 22% protein), respectively. The energy level had no effect (P < 0.05) on feed intake and weight gain in all experimental period. The results of this study showed that with increasing energy and protein levels, most blood parameters increased in ostriches but total cholesterol did not.

Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis

Introduction Antipsychotics are associated with bodyweight gain and metabolic disturbance. Previous meta-analyses were limited to mainly antipsychotic switch studies in patients with a diagnosis of schizophrenia or psychosis with short follow-up periods. The present meta-analysis aimed to analyse the impact of weight change in antipsychotic-naive and antipsychotics switch patients and whether body weight change depended on diagnosis. Method We performed a meta-analysis of clinical trials of antipsychotics that reported weight change, irrespective of psychiatric diagnosis. Outcome measure was body weight change. Studies were classified into antipsychotic-naive and antipsychotic-switch. Forest plots stratified by antipsychotic and the duration of antipsychotic use were generated and results were summarised in figures. Results In total, 404 articles were included for the quantitative synthesis. 58 articles were on antipsychotic naive patients. In the antipsychotic naive group, all antipsychotics resulted in body weight gain. In the antipsychotic switch group, most antipsychotics likewise resulted in bodyweight gain, with exception of amisulpride, aripiprazole and ziprasidone that showed no body weight gain or even some weight loss after switching antipsychotics. Diagnosis was not a discriminating factor of antipsychotic induced weight change. Conclusion Antipsychotic use resulted in substantial increase in body weight in antipsychotic-naive patients. In antipsychotic-switch patients the weight gain was mild and not present in amisulpride, aripiprazole and ziprasidone. In both groups, weight gain was irrespective of the psychiatric diagnosis.

Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study

Background: People with schizophrenia have a 15–20-year reduction in life expectancy, driven in part by the metabolic effects of antipsychotics. Clozapine is associated with the highest rates of weight gain. As clozapine remains the most effective antipsychotic for treatment-resistant schizophrenia (TRS), identifying treatments to ameliorate clozapine-induced weight gain (CIWG) is urgently needed to reduce this morality gap. Methods: We retrospectively analysed digital health records of patients with TRS aged 18–65 newly initiated on clozapine at four tertiary hospitals in south-east Queensland from 1 March 2017 to 30 June 2019. Our primary outcome was the effect of metformin on change in percentage bodyweight at 12 months after clozapine initiation, with secondary outcome being proportion with >5% or >7% bodyweight change. We also explored impact on bodyweight change of other variables including sex, tobacco smoking, type 2 diabetes (T2DM), age, clozapine level and dose and clozapine/norclozapine ratio. Results: Among 90 patients initiated on clozapine, metformin use ( n = 48) was associated with a smaller increase in percentage bodyweight (1.32% versus 5.95%, p = 0.031), lower rates of >7% gain in bodyweight (37.8% versus 63.0%, p = 0.025) but not >5% gain in bodyweight. Age below the median (32.0 years) was associated with greater bodyweight gain (5.55% versus 1.22%, p = 0.046). Sex, tobacco smoking, T2DM, clozapine dose and level and clozapine/norclozapine ratio were not associated with differences in change in bodyweight. Conclusion: In this small retrospective cohort study, use of metformin within 12-months of clozapine initiation was associated with a statistically and clinically significant reduction in CIWG. Although there is increasing evidence for the role of metformin to ameliorate bodyweight gain at time of clozapine initiation, our findings need replication and testing in a randomised controlled trial before recommending metformin co-commencement with clozapine as standard clinical practice.